Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.
https://european-biotechnology.com/wp-content/uploads/2024/04/flag-1192625_1920.jpg9601920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-06-22 10:59:262020-06-22 10:59:26Illumina and Epidarex Capital invest in post-Brexit UK
Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.
https://european-biotechnology.com/wp-content/uploads/2024/04/HCV.jpg393562Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-06-18 06:24:002020-06-18 06:24:00Novel adjuvant teases T cells to respond to HCV
https://european-biotechnology.com/wp-content/uploads/2024/04/novel-coronavirus-sars-cov-2_49680384436_o.jpg18011800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-06-17 09:08:432020-06-17 09:08:43First drug found to reduce COVID-19-mortality
https://european-biotechnology.com/wp-content/uploads/2024/04/Curevac-vaccine_printer.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-06-16 08:32:092020-06-16 08:32:09Germany puts €300m in CureVac AG for COVID-19 vaccine
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2020-06-12 12:53:522020-06-12 12:53:52New CEO at Ipsen
Emperor Nero, reportedly, fiddled as Rome burned in 64 A.D., much like society for a long time ignored and repressed the pending crisis of antimicrobial resistance (AMR).
https://european-biotechnology.com/wp-content/uploads/2024/04/AiCuris_PREP_kl.jpg239425Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-06-12 11:36:002020-06-12 11:36:00Antimicrobial resistance This is not the time to wait. This is the time to act.
https://european-biotechnology.com/wp-content/uploads/2024/04/Genmab.jpg387568Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-06-10 12:45:032020-06-10 12:45:03Abbvie and Genmab team up in oncology
Illumina and Epidarex Capital invest in post-Brexit UK
Latest NewsIllumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.
Biognosys appoints new Chairman
AppointmentsSchlieren-based proteomics specialist Biognosys AG announces the appointment of Dr Patrick Vink as Chairman of the board.
Novel adjuvant teases T cells to respond to HCV
Latest NewsResearchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.
First drug found to reduce COVID-19-mortality
Latest NewsA clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients.
Germany puts €300m in CureVac AG for COVID-19 vaccine
Latest NewsIn the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
New CEO at Ipsen
AppointmentsDavid Loew, formerly executive vice president of Sanofi Pasteur, was appointed as CEO of French Ipsen Pharma SA at the beginning of July.
Antimicrobial resistance This is not the time to wait. This is the time to act.
Sponsored PublicationsEmperor Nero, reportedly, fiddled as Rome burned in 64 A.D., much like society for a long time ignored and repressed the pending crisis of antimicrobial resistance (AMR).
Abbvie and Genmab team up in oncology
Latest NewsAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics signs US$1.2bn deal with Eli Lilly
Latest NewsEvox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Calliditas Therapeutics raise US$90m in Nasdaq IPO
Latest NewsSwedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.